Description
LGD-4033, also known as Ligandrol, is a SARM discovered by Ligand Pharmaceuticals and currently under licensed development by Viking Therapeutics. There has been a lot of research into the efficacy of LGD-4033, but very little published research. Ligandrol has exhibited desirable in vivo efficacy on skeletal muscle and bone measurements in animal models of disease. There is only one published study on the effects of LGD-4033 in humans. In 2013, Bhasia et al. conducted a rigorous 3-week placebo-controlled study of 76 healthy men aged 21 – 50 years old. During this study participants were randomly assigned to be given a placebo, 0,1, .0,3 or 1mg of LGD-4033 for 21 days. There was a dose dependent increase in lean body mass. There was also a dose dependent increase in strength as measured by stair climbing speed and power. Adverse effects were not noted 5. The sample size was small, as the study’s primary aim was to establish safety and tolerability, rather than efficacy. As such, the 3-week study duration was not designed to demonstrate maximal effects on muscle mass and strength. Therefore, larger and longer studies are needed to access the efficacy of LGD-4033.
Reviews
There are no reviews yet.